Leuphasyl is the trade name for pentapeptide-18, which the app files as a topical cosmetic neuropeptide with an INCI name of Pentapeptide-18. Akhan and colleagues, writing in Chemistry & Biodiversity in 2026, call it "another cosmeceutical peptide classified as a neurotransmitter inhibitor that operates similarly to Botulinum neurotoxins (BoNTs)".1 A second paper from the same Istanbul University group describes "Pentapeptide-18 (Leuphasyl®), a bioactive peptide known for its neuromodulatory properties".2 A third paper from that group lists the sequence as Tyr-Ala-Gly-Phe-Leu and describes it as "derived from botulinum neurotoxin as a biommimetic peptide", a different account of its design from the enkephalin-inspired one in the app's notes.3

The app's notes describe it as enkephalin-inspired, frequently paired with Argireline, and state that independent evidence is limited. The app grades the evidence as limited. The studies read for the app's entry are laboratory and computer-model studies; the 2026 Chemistry & Biodiversity paper reports support from the Scientific Research Projects Coordination Unit of Istanbul University, and no controlled trial in people was identified in PubMed or ClinicalTrials.gov.1

The proposed mechanism is a relaxation of expression lines by reducing acetylcholine release at the nerve-muscle junction. Akhan and colleagues, citing earlier work, write that "Leuphasyl mimics endogenous enkephalins, binding to enkephalin receptors on nerve cells to reduce neuronal excitability and acetylcholine release".1 A 2025 review of cosmetic peptides (Zdrada-Nowak and colleagues, International Journal of Molecular Sciences) lists Leuphasyl, made by Lipotec S.A. of Barcelona, as "Designed to modulate calcium channels by mimicking the action of enkephalins".4 The review adds that "It blocks the calcium channels in neurons in a similar manner to enkephalins, thereby inhibiting the release of acetylcholine".4 This is a design rationale given in reviews and papers on cosmetic peptides; the 2026 papers described here did not test it in a nerve-muscle preparation or in people.

Computer docking against skin-ageing targets

The 2026 Chemistry & Biodiversity paper docked Leuphasyl against collagen-degrading enzymes (MMP-1, MMP-8, MMP-13) and SIRT-1, a longevity-related protein.1 For MMP-1 the docking scores were "–6.37 kcal/mol and –10.67 kcal/mol" for Vialox and Leuphasyl respectively.1 For SIRT-1 the order reversed: "−9.97 and −8.58 kcal/mol" for Vialox and Leuphasyl, "suggesting a stronger predicted affinity for Vialox".1 For MMP-13 the authors write that "Leuphasyl demonstrates superior interaction with catalytic and pocket residues, supporting its stronger predicted inhibitory potential".1 These are predicted binding scores from simulations, not measured enzyme inhibition. A separate paper in Computational Biology and Chemistry (Akhan and colleagues, 2026) docked pentapeptide-18 against TGF-β, TNF-α, MAPK, PI3K/AKT and NF-κB; the PubMed record gives no scores.2

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
95%
Typical dose
2–5%
Route
Topical
Time to peak
~0.5 h

The second column holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~4 hNo half-life was reported in the sources identified
Bioavailability95%No measured figure reported; an in silico prediction gives "limited oral bioavailability" for Leuphasyl and Vialox, an oral prediction for a topical product3
Time to peak~0.5 hNo measured figure reported
Duration12 hNo measured figure reported

The app's notes state that it is a topical ingredient with negligible systemic absorption, so systemic tracking is not applicable and the modeled curve does not really reflect how it works. The app lists a bioavailability of 95% beside that note, and the sources identified give no measured figure for either statement. In the 2026 Chemistry & Biodiversity paper, predicted properties were that "both peptides comply with Lipinski's rule of five", and "based on Log Kp values from ADME analysis, Leuphasyl demonstrates higher potential for cellular permeation" than Vialox.1

4

Human studies

No controlled trial of Leuphasyl in people was identified in PubMed or ClinicalTrials.gov; the three PubMed records for "Leuphasyl" were laboratory and computer-model papers. The 2026 Chemistry & Biodiversity paper states that "Clinical studies show Leuphasyl significantly reduces the depth of expression wrinkles, particularly in the forehead and periorbital areas, with efficacy observed even at 0.5% concentration".1 That statement cites earlier work whose text could not be retrieved here, so its design, size, comparator and funding are not summarised, and it is not counted among the sources.

The table lists the laboratory studies instead; none involved people.

Table 4.1Human studies3 rows
Study and yearDesignPeopleDose and lengthMain result
Akhan and colleagues, Chemistry & Biodiversity 20261Docking, molecular dynamics (50 and 100 ns), ADME prediction and an MTT cell assayNone; HaCaT human immortalized keratinocytesEight concentrations from 0.005 to 1 mg/mL, 24 h in cells, three biological replicatesViability at 1 mg/mL was 103.46 ± 1.72% for Leuphasyl and 88.39 ± 0.71% for Vialox, against controls of 100.00%; MMP-1 docking score –10.67 kcal/mol for Leuphasyl and –6.37 kcal/mol for Vialox
Akhan and colleagues, Computational Biology and Chemistry 20262Spectroscopy, density functional theory, docking, molecular dynamics, ADMET predictionNoneNot given in the PubMed recordThe authors describe the findings as "reinforcing its potential as a safe, effective, and non-invasive candidate for advanced anti-aging skin care applications"; the record gives no numbers
Akhan and colleagues, Cell Biochemistry and Biophysics 20263Docking, MM-GBSA, molecular dynamics, ADMET prediction and an MTT assay in cancer cell linesNone; MDA-MB-231 and PC3 cancer cellsNot given in the PubMed recordDocking scores of -10.63 to -7.59 kcal/mol across both peptides; most pronounced cytotoxic effects in MDA-MB-231 and PC3 cells

Deeper analysis: Akhan and colleagues, Chemistry & Biodiversity 2026

The authors are in the Department of Physics at Istanbul University and the Department of Bioengineering at Yildiz Technical University.1 The design was computational plus one cell assay: docking against MMP-1, MMP-8, MMP-13 and SIRT-1, molecular dynamics, ADME and toxicity prediction, and an MTT viability assay on HaCaT cells with the peptide bought from Cayman Chemical.1 In the cell assay, the authors state that "Both peptides showed no cytotoxicity at concentrations up to 1 mg/mL in HaCaT cells".1 They also report that "cell viability percentages increased as a result of application with Leuphasyl peptide", and describe Leuphasyl as "slightly enhancing proliferation".1 The authors state that this increase was statistically significant at 0.025, 0.050, 0.1 and 0.25 mg/mL.1 In the simulations, "both peptides maintained conformational stability throughout the 100 ns trajectory".1 For SIRT-1 the authors report that Vialox formed a more stable and persistent interaction than Leuphasyl, whose hydrogen bonding with VAL412 lasted 43% of the 100 ns trajectory.1 The less favourable result for Leuphasyl was SIRT-1, where its predicted binding energy (−8.58) was weaker than Vialox (−9.97).1 The paper reports no wrinkle, skin, nerve or muscle measurement and no adverse-event data, because no person or animal was studied. The authors close with a call for "further investigation of their efficacy through advanced in vivo studies and clinical trials".1 The paper states "The authors declare no conflicts of interest"; funding is from the university unit named above, and the authors also report using laboratory infrastructure at Yildiz Technical University established with TUBITAK support.1

Deeper analysis: Akhan and colleagues, Computational Biology and Chemistry 2026

The only text read for this study is its PubMed record, so no results table, limitations section or funding statement was available.2 The record says the work combined density functional theory calculations, spectroscopy, docking, molecular dynamics and ADMET prediction.2 Its opening statement that Leuphasyl "has demonstrated the ability to mitigate wrinkle formation by inhibiting neurotransmitter release" is background in the record, not a result of this study.2 The authors declare "no known competing financial interests or personal relationships", and the record lists no grants.2

Deeper analysis: Akhan and colleagues, Cell Biochemistry and Biophysics 2026

This paper tested Leuphasyl and Vialox against cancer targets and cancer cell lines, which is a different question from cosmetic use on skin.3 The record reports the highest docking affinity for "EGFR-Leuphasyl (-10.63 kcal/mol)", and the authors write that "both peptides may exhibit selective anticancer effects".3 The record states "The authors declare no competing interests" and lists no grants; no person or animal was studied.3

5

Doses reported in studies and on labels

Sources in this part

  1. 1Akhan et al., 2026
Table 5.1Doses reported in studies and on labels3 rows
SourcePreparation and doseContext
App's figure2–5% serum concentration, topicalThe app's typical dose range, with a stated unit of %
Akhan and colleagues, 2026, citing earlier clinical work10.5% concentrationDescribed as an efficacy level in clinical studies; the cited work was not retrieved, so design and size are unknown
Akhan and colleagues, 202610.005 to 1 mg/mL in the culture medium of HaCaT cells for 24 hCell viability assay, no people

No product label or regulator document for Leuphasyl was among the sources read.

6

Side effects reported

Sources in this part

  1. 1Akhan et al., 2026

No adverse-event data from a trial in people were identified in the sources. The 2026 Chemistry & Biodiversity paper states, citing earlier work, "Importantly, Leuphasyl is well tolerated, with minimal adverse effects reported in topical applications".1 The only direct safety measure in the sources is the HaCaT cell viability result, in which viability at 1 mg/mL was 103.46 ± 1.72% for Leuphasyl.1 The same paper's computer toxicity prediction for Leuphasyl was active for respiratory toxicity, carcinogenicity and nephrotoxicity, with respiratory toxicity the highest at 75%, although its conclusions describe both peptides as nontoxic.1

  • The sources identified give no half-life, time to peak or duration for Leuphasyl, and no measurement of how much reaches or passes through skin.
  • No controlled trial in people was identified in PubMed or ClinicalTrials.gov, and the earlier clinical work cited by Akhan and colleagues could not be retrieved.
  • The 2026 papers read use docking, simulation and cell assays, and the authors themselves call for in vivo studies and clinical trials.1
  • The sources describe its design differently (enkephalin mimic acting on calcium channels in one review, derived from botulinum neurotoxin in another paper), and none tested the proposed nerve-muscle mechanism directly.4,3
  • Regulatory and anti-doping status are not covered, because no regulator document was retrieved.
8

Frequently asked questions

What is Leuphasyl?

Leuphasyl is the trade name for pentapeptide-18, which the app files as a topical cosmetic neuropeptide.

What is the half-life of Leuphasyl?

The app lists a half-life of about 4 hours, and the sources identified report no half-life figure for it.

What is the time to peak for Leuphasyl?

The app lists about 0.5 hours, and the sources identified report no measured time to peak.

What is the bioavailability of Leuphasyl?

The app lists 95% beside a note of negligible systemic absorption, and the sources identified give no measured figure. An in silico prediction in one 2026 paper gives "limited oral bioavailability", which concerns an oral route.3

How does Leuphasyl work?

It is described as mimicking enkephalins to reduce acetylcholine release at the nerve-muscle junction, a rationale from papers and reviews rather than a tested result in these studies.1,4

Has Leuphasyl been tested in people?

No controlled trial in people was identified in PubMed or ClinicalTrials.gov. A 2026 paper cites clinical studies of wrinkle depth, which were not retrieved here.1

Was Leuphasyl toxic to skin cells in laboratory tests?

In HaCaT keratinocytes, a 2026 paper reports no cytotoxicity at concentrations up to 1 mg/mL.1 Viability at 1 mg/mL was 103.46 ± 1.72% for Leuphasyl, and a different paper reported cytotoxic effects of Leuphasyl and Vialox in MDA-MB-231 and PC3 cancer cell lines.1,3

What strength does the app list for Leuphasyl?

The app lists a typical range of 2 to 5%. A 2026 paper cites clinical work reporting efficacy at 0.5%, which the app's range does not include.1

10

References

  1. Akhan D, Bicak B, Kurtur OB, Budama-Kilinc Y, Gunduz SK. Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications. Chem Biodivers 2026;23(5):e02546. PMID 42116636
  2. Akhan D, Bicak B, Akalin E, Gunduz SK. Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis. Comput Biol Chem 2026;123:108952. PMID 41722287
  3. Akhan D, Bicak B, Akman G, Kecel Gunduz S. In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides. Cell Biochem Biophys 2026;84(3):3909-3950. PMID 42412310
  4. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci 2025. PMID 40565185